Application No.: 08/459,141

Page 6

APPENDIX A

"MARKED UP" CLAIMS ILLUSTRATING THE AMENDMENTS MADE TO THE CLAIMS OF 08/459141 WITH ENTRY OF THIS AMENDMENT

- 10. (Amended) An immunogenic composition comprising a truncated, membrane-free derivative of a polypeptide comprising a membrane-binding domain and antigenic determinants capable of raising neutralizing antibodies against in vivo challenge by a pathogen, wherein said derivative:
 - (a) is devoid of the membrane-binding domain whereby the derivative is free of membrane, and
 - (b) has exposed antigenic determinants capable of raising neutralizing antibodies against in vivo challenge by the pathogen.
- 11. (Twice Amended) An immunogenic composition according to Claim <u>25</u> [16] wherein the derivative is a derivative of glycoprotein D.
- 12. (Twice Amended) An immunogenic composition according to Claim <u>25</u> [16] wherein the derivative is a derivative of glycoprotein C.
- 13. (Twice Amended) An immunogenic composition according to Claim <u>25</u> [16] wherein the derivative is a derivative of glycoprotein B.
- 14. (Twice Amended) A method of producing an immunogenic composition according to any one of Claims 10, 11, 12, or 13 [1, 2, 3, or 4], said method comprising preparing a nucleic acid encoding said derivative, incorporating said nucleic acid into an expression vector, introducing said vector into a host cell, and collecting the derivative as a secretion product.
- 15. (Twice Amended) A method according to Claim 14 [10] wherein the host cell is a stable eukaryotic cell line.
- 16. (Twice Amended) A method according to Claim 15 [11] wherein the host cell is a mammalian cell line.
- 17. (Twice Amended) A method according to Claim 15 [11] wherein the cell line is deficient in the production of dhfr and the vector contains a dhfr selectable marker.
- 18. (Twice Amended) A method according to Claim 14 [10] wherein the derivative is a glycoprotein D of herpes simplex virus type 1 or type 2.

Application No.: 08/459,141

Page 7

- 19. (Twice Amended) A method according to Claim 18 [10] wherein the derivative comprises the first 300 amino acid residues of the glycoprotein D.
- 20. (Twice Amended) An immunogenic composition according to Claim <u>25</u> [16] wherein said immunogenic composition comprises a mixture of glycoproteins or glycoprotein derivatives.
- 21. (Twice Amended) An immunogenic composition according to Claim <u>20</u> [5] wherein said mixture comprises glycoprotein C or a derivative thereof and glycoprotein D or a derivative thereof.
- 22. (Twice Amended) An immunogenic composition according to Claim <u>20</u> [5] wherein said mixture comprises glycoprotein D or a derivative thereof.
- 23. (Twice Amended) An immunogenic composition according to Claim <u>22</u> [7] wherein said mixture further comprises glycoprotein B or a derivative thereof.
- 25. (Amended) An immunogenic composition according to Claim 10 wherein the derivative is a derivative of a herpes glycoprotein.
- 26. (Amended) An immunogenic composition according to Claim <u>25</u> [16] wherein the derivative is a derivative of herpes simplex virus type 1 or type 2, and the pathogen is herpes simplex type 1 and/or type 2.
- 27. (Amended) An immunogenic composition according to Claim <u>25</u> [16] wherein said derivative is produced in a stable eukaryotic cell line.
- 28. (Amended) An immunogenic composition according to Claim <u>27</u> [18] wherein said cell line is a mammalian cell line.
- 29. (Amended) An immunogenic composition according to Claim 11 [2] wherein said derivative comprises the first 300 residues of glycoprotein D.
- 30. (Amended) A method according to Claim 14 [10] wherein the derivative is a derivative of glycoprotein C.
- 31. (Amended) A method according to Claim 14 [10] wherein the derivative is a derivative of glycoprotein B.
- 32. A nucleic acid encoding a truncated, membrane-free derivative of a polypeptide comprising a membrane-binding domain and antigenic determinants capable of raising neutralizing antibodies against in vivo challenge by a pathogen, wherein said derivative is:

Application No.: 08/459,141
Page 8

(a) is devo

- (a) is devoid of the membrane-binding domain whereby the derivative is free of membrane, and
- (b) has exposed antigenic determinants capable of raising neutralizing antibodies against in vivo challenge by the pathogen.
- 33. (Amended) The nucleic acid of Claim 32 [23] wherein the derivative is a derivative of a herpes glycoprotein.
- 34. (Amended) The nucleic acid of Claim 33 [24] wherein the derivative is a derivative of a glycoprotein of a herpes simplex virus type 1 or type 2, and the pathogen is herpes simplex type 1 and/or type 2.
- 35. (Amended) An expression vector comprising a nucleic acid according to Claim 32 [24].
- 36. (Amended) A stable host cell comprising an expression vector according to Claim 35 [26].
- 37. (Amended) A host cell according to Claim <u>36</u> [27] wherein the host cell is a eukaryotic cell.
- 38. (Amended) A host cell according to Claim <u>37</u> [28] wherein the host cell is a mammalian host cell.
- 39. (Amended) A method of producing a truncated, membrane-free derivative of a polypeptide comprising a membrane-binding domain and antigenic determinants capable of raising neutralizing antibodies against in vivo challenge by a pathogen, said method comprising:
 - (a) culturing the host cell of Claim <u>36</u> [27]; and
 - (b) recovering the derivative from the culture.
- 40. An immunogenic composition comprising a truncated, membrane-free derivative of a polypeptide comprising a membrane-binding domain and antigenic determinants capable of raising neutralizing antibodies against in vivo challenge by a pathogen, wherein said derivative:
 - (a) is devoid of the membrane-binding domain whereby the derivative is free of membrane, and
 - (b) has exposed antigenic determinants capable of raising neutralizing antibodies against in vivo challenge by the pathogen, wherein the pathogen is a virus.

Application No.: 08/459,141

Page 9

- 41. An immunogenic composition comprising a truncated, membrane-free derivative of a polypeptide comprising a membrane-binding domain and antigenic determinants capable of raising neutralizing antibodies against in vivo challenge by a pathogen, wherein said derivative:
 - (a) is devoid of the membrane-binding domain whereby the derivative is free of membrane, and
- (b) has exposed antigenic determinants capable of raising neutralizing antibodies against in vivo challenge by the pathogen, wherein said pathogen is a virus selected from the group consisting of herpes virus, influenza virus, foot and mouth disease virus, hepatitis virus, vesicular stomatitis virus and rabies virus.